Credits Available: 4.75 AMA PRA Category 1 Credit™ & 4.75 MOC points

Description: The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.

John Hopkins Medicine Logo

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Pediatrics, Neurology, Orthopedic Medicine/Sports Medicine, Physiatry/Rehabilitation, Neuromuscular

Mary Ann Picone

Holy Name Medical Center
Medical Director

I have been a neurologist for over 20 years and have been principal investigator in numerous clinical research studies. I am an author of MS for the Non Neurologist. Given the new information and medications available regarding treatments for Alzheimer's Disease and mild cognitive impairment, these modules should prove to be very helpful in our understanding of earlier diagnosis and treatment of this disorder.